Press Releases Press Releases Year: - Any -2019201820172016201520142013 March 05, 2019 Summary ToggleMelinta Therapeutics to Report Fourth Quarter and Year-End 2018 Financial Results on March 13, 2019 February 25, 2019 Summary ToggleMelinta Therapeutics Announces Closing of Initial $75 Million Vatera Convertible Loan Funding February 21, 2019 Summary ToggleMelinta Therapeutics Announces One-for-Five Reverse Stock Split February 04, 2019 Summary ToggleMelinta Therapeutics Provides Corporate Updates December 19, 2018 Summary ToggleJohn H. Johnson Agrees to Become Permanent Chief Executive Officer of Melinta Therapeutics December 19, 2018 Summary ToggleMelinta Therapeutics Announces Commitment for New Credit Facility of Up to $135 Million November 27, 2018 Summary ToggleMelinta Therapeutics Granted European Commission Marketing Authorization for Vabomere® (meropenem and vaborbactam) November 07, 2018 Summary ToggleMelinta Therapeutics Reports Third Quarter 2018 Financial Results October 31, 2018 Summary ToggleMelinta Therapeutics Announces Appointment of Bruce L. Downey to Board of Directors October 29, 2018 Summary ToggleMelinta Therapeutics Announces Positive Top-Line Results in Phase III Trial of Baxdela® (delafloxacin) for Treatment of CABP Pagination First page First Previous page Previous Page 1 Current page 2 Page 3 Page 4 … Next page Next Last page Last
Press Releases Year: - Any -2019201820172016201520142013 March 05, 2019 Summary ToggleMelinta Therapeutics to Report Fourth Quarter and Year-End 2018 Financial Results on March 13, 2019 February 25, 2019 Summary ToggleMelinta Therapeutics Announces Closing of Initial $75 Million Vatera Convertible Loan Funding February 21, 2019 Summary ToggleMelinta Therapeutics Announces One-for-Five Reverse Stock Split February 04, 2019 Summary ToggleMelinta Therapeutics Provides Corporate Updates December 19, 2018 Summary ToggleJohn H. Johnson Agrees to Become Permanent Chief Executive Officer of Melinta Therapeutics December 19, 2018 Summary ToggleMelinta Therapeutics Announces Commitment for New Credit Facility of Up to $135 Million November 27, 2018 Summary ToggleMelinta Therapeutics Granted European Commission Marketing Authorization for Vabomere® (meropenem and vaborbactam) November 07, 2018 Summary ToggleMelinta Therapeutics Reports Third Quarter 2018 Financial Results October 31, 2018 Summary ToggleMelinta Therapeutics Announces Appointment of Bruce L. Downey to Board of Directors October 29, 2018 Summary ToggleMelinta Therapeutics Announces Positive Top-Line Results in Phase III Trial of Baxdela® (delafloxacin) for Treatment of CABP Pagination First page First Previous page Previous Page 1 Current page 2 Page 3 Page 4 … Next page Next Last page Last
